Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus–driven oropharyngeal cancer and are associated with recurrence

Human papillomavirus 16 (HPV16) E6 antibodies may be an early marker of the diagnosis and recurrence of human papillomavirus–driven oropharyngeal cancer (HPV‐OPC).

[1]  N. Freedman,et al.  Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer , 2017, Journal of the National Cancer Institute.

[2]  M. Wiesenfarth,et al.  Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16‐driven oropharyngeal squamous cell carcinoma , 2017, International journal of cancer.

[3]  H. Quon,et al.  Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. , 2017, Oral oncology.

[4]  Jeremy MG Taylor,et al.  E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma , 2016, Clinical Cancer Research.

[5]  Daria A. Gaykalova,et al.  Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer , 2015, Cancer Prevention Research.

[6]  K. Anderson,et al.  HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx , 2015, Clinical Cancer Research.

[7]  Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection , 2014, Cancer Causes & Control.

[8]  R. Tachezy,et al.  Markers of HPV infection and survival in patients with head and neck tumors , 2013, International journal of cancer.

[9]  Paolo Vineis,et al.  Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Ahrens,et al.  Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. , 2013, Journal of the National Cancer Institute.

[11]  S. Franceschi,et al.  Biological activity of probable/possible high‐risk human papillomavirus types in cervical cancer , 2013, International journal of cancer.

[12]  M. Pawlita,et al.  Complex Etiology Underlies Risk and Survival in Head and Neck Cancer Human Papillomavirus, Tobacco, and Alcohol: A Case for Multifactor Disease , 2012, Journal of oncology.

[13]  R. Malekzadeh,et al.  InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. , 2012, Journal of the National Cancer Institute.

[14]  Esther Kim,et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Pawlita,et al.  Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study , 2011, Infectious Agents and Cancer.

[16]  P. Brennan,et al.  Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. , 2011, International journal of epidemiology.

[17]  D. Heron,et al.  Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Westra,et al.  Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus‐associated head and neck cancer based on a prospective clinical experience , 2010, Cancer.

[19]  M. Pawlita,et al.  Homogeneous Amplification of Genital Human Alpha Papillomaviruses by PCR Using Novel Broad-Spectrum GP5+ and GP6+ Primers , 2008, Journal of Clinical Microbiology.

[20]  S. Franceschi,et al.  Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea , 2007, Cancer Epidemiology Biomarkers & Prevention.

[21]  M. Pawlita,et al.  Suppression of non-specific binding in serological Luminex assays. , 2006, Journal of immunological methods.

[22]  Peter J. F. Snijders,et al.  Bead-Based Multiplex Genotyping of Human Papillomaviruses , 2006, Journal of Clinical Microbiology.

[23]  Markus F Templin,et al.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. , 2005, Clinical chemistry.

[24]  N. Nguyen,et al.  Combined chemotherapy and radiation therapy for head and neck malignancies , 2002, Cancer.

[25]  P. Albert,et al.  Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.

[26]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[27]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.